M&A / Deals Ambrosia adds a megaround for obesity drugs BioPharma DiveThe $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing.M&A / DealsMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive The $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing. M&A / DealsMetabolic & GLP-1Read full story Post navigation Previous: FDA approves new high dose Spinraza regimen for SMANext: FDA Approves First New Molecular Entity Under National Priority Voucher Program Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
